leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 10:05:42 - browse：8

Primary care exam 01 — ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and Medtronic have run studies that showed renal denervation leads to a modest decrease in blood pressure. Adam Berry/Getty Images

The Food and Drug Administration approved a surgical system used to reduce blood pressure from Recor Medical, the company announced Wednesday. The treatment, called renal denervation, is controversial in the cardiology community due to its unclear efficacy.

Renal denervation is a treatment for patients who cannot manage standard doses of blood pressure medication — whether because the drugs aren’t effective enough for them, create overwhelming side effects, or become too cumbersome. The therapy, which is meant to be a one-time procedure, is administered via a catheter. Electrodes on the catheter then emit radiofrequency or ultrasound energy to block nerve signals from the kidneys that increase blood pressure.

The therapy, a simple procedure to reduce the blood pressure of millions of Americans, was once seen as a boon for cardiologists and device makers. But a large-scale clinical trial from Medtronic in 2014 called renal denervation’s efficacy into question, as it did not significantly reduce blood pressure compared to placebo treatments.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Telehealth startups turn to complex chronic diseases

knowledge

WSS

Dairy farmers resist CDC push for PPE against bird flu virus

Midwives could help bridge maternal health disparities in the U.S.

Chamber of Commerce, DOJ clash in court over drug prices

Senate bill would ban some hospital facility fees

How the messy conversation about Dolly changed bioethics

Shionogi licenses Pompe disease therapy from Maze Therapeutics

entertainment

leisure time

focus

Psychedelics group wrestles with new pharma identity

White House Covid adviser calls on docs to combat misinformation

Activists slam private health insurers over coverage restrictions

Covid’s new normal has set in amid another rise in cases

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Drug repurposing or repositioning? The language matters

Senate bill would ban some hospital facility fees

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare says breakthrough device reimbursement rule to come by summer

entertainment

Akili changes sales model for its ADHD video game treatment

Patients, doctors press FTC to beef up hospital merger scrutiny

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Medicare says breakthrough device reimbursement rule to come by summer

Readout LOUD podcast: brain research, obesity drug sales, Novartis

How the messy conversation about Dolly changed bioethics

knowledge

knowledge

focus

leisure time